30 closest matches · ranked by relevance
Advanced Nonhematological Malignancies · Non-Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants
Cancer
Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
Advanced Solid Tumors
Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants
Advanced Nonhematologic Malignancies
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 3; 7; 3 Participants
Acute Myeloid Leukemia · Lymphoblastic Leukemia · Acute Leukemia
Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Gastric Adenocarcinoma · Esophageal Cancer · Hepatocellular Carcinoma
Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Hematologic Malignancies
Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants
B-cell Follicular Lymphoma · B-cell Marginal Zone Lymphoma · Diffuse Large B-cell Lymphoma
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 1; 2; 0; 1 participants
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
Lymphoma · Leukemia
Primary: Composite Success Rate — 100; 75; 84 Percentage of participants
Melanoma
Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants
Cervical Cancer · Renal Cancer · Urothelial Cancer
Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…
Acute Myeloid Leukemia · Higher Risk Myelodysplastic Syndrome
Primary: Stage 1: Dosing Schedule of Low-dose Cyclophosphamide — 6; 6 Participants
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Malignant Melanoma · Head and Neck Cancer
Primary: Tissue and Hematopoietic Stem Cell Collection — 8 Participants
Solid Tumor · Lymphoma · Peripheral T-Cell Lymphoma
Primary: Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant…
Carcinoma, Non-Small-Cell Lung · Colorectal Cancer · Malignant Melanoma
Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting…
Advanced Cancer
Primary: Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level — 1; 3; 0; 2 Participants
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Ewing Sarcoma · PEComa · Epithelioid Sarcoma
Primary: Maximum Tolerated Dose of ABI-009 — 100 mg/m^2
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days — 57; 29 Participants — p=0.7186
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Peripheral T-cell Lymphoma NOS · Mycosis Fungoides · Sezary Syndrome
Primary: Maximum Tolerated Dose (MTD) of Interleukin 15 — NA; NA mcg/kg
Advanced Melanoma · Non-small Cell Lung Cancer · Renal Cell Carcinoma
Primary: Safety and Tolerability Measured by Assessing Serious Adverse Events (SAEs)and Adverse Events (AEs) — 1; 3; 2; 2 Participants